中國生物科技服務(08037.HK)與石藥集團簽署戰略合作意向書
格隆匯3月24日丨中國生物科技服務(08037.HK)發佈公吿,2022年3月23日,公司與石藥集團(01093.HK)訂立無法律約束力的戰略合作意向書。根據意向書,公司及石藥集團擬於意向書簽署後一年的有效期內,尋求在相關以股權為基礎的投資或公司已開展的項目上進行一項或多項戰略合作。
董事會認為,與石藥集團的潛在戰略合作可能會為公司正在發展的大部分(如非全部)精準治療業務帶來寶貴的戰略投入。倘若合作成事,董事會相信,其將會為公司的股東產生重大價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.